Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Distinguished Professor and Academic Tenure of Chemistry and also Enrico Fermi Distinguished Chair in Molecular Spectroscopy at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, Synchrocyclotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc

Oncology, Human Cancer tissues

Born in Rome the 7/12/1949, 5 children, held the medical degree at the University of Rome “La Sapienza” with full honour. VC is specialist in Clinical of Infectious Diseases (University of Rome) and in Hygiene and Public Health (University of Pisa), and PhD in Immunology (Brunnel University, England). His doctorate and post-doc experience have been carried out at the Clinical Research Centre in Harrow (England). He has been Assistant in Microbiology, and Associate professor in Immunology at the University of Pisa. Since 2000 to now, VC is Full Professor of Immunology and Director of the UNESCO Chair in Biotechnology at the University of Rome Tor Vergata. VC has been also President (2007-2010) of the Board of the National Institute for Infectious Diseases “Lazzaro Spallanzani” in Rome, Italy. He is consultants for several agencies of the United Nations (UNESCO, UNDP, OMS) and is scientific coordinator of several European and international Projects. VC has been Scientific Director and member of the Board of the International Reference Centre for AIDS “Chantal Biya” in Yaoundé, Cameroon and President of the University Spinoff Eurobiopark (European Group of Biotechnology at the Tior Vergata Science Park). VC published over 260 scientific publications on peer-review journals (Nature, Journal of Immunology, Infection and Immunity, Journal of Infectious Diseases, Immunology, Clinical Experimental Immunology, A, IDS, AIDS and Human Retrovirus Journal, etc.) in the sector of Microbial Immunology and Infectious Diseases, with special focus on AIDS and Tuberculosis.

Immunology, Virology, Biotechnology

Sergey Suchkov received his MD from Astrakhan State Medical University. In 1985, he received his PhD from the I M Sechenov Moscow Medical Academy and in 2001, his Doctorship Degree at the Nat Institute of Immunology, Russia. From 1987 through 1989, he was a Senior Researcher, Koltzov Institute of Developmental Biology. From 1989 through 1995, he was a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, he was the Chair of the Department of Clinical Immunology, Moscow Clinical Research Institute. He was an Exe Secretary-in-Chief of the Editorial Board of Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, he is a Chair at the Department for Personalized and Translational Medicine, I M Sechenov First Moscow State Medical University. He is a Member of the New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research) and PMC (Personalized Medicine Coalition), Washington, USA.

Translational Medicine

Dr. Hongjun Wang has completed her PhD from China Agricultural University and postdoctoral studies at the University of Rome, “La Sapienza” and St. Jude Children’s Hospital. She was an instructor and Assistant Professor at the Harvard Medical School/Beth Israel Deaconess Medical Center from 2001-2011. She is now a full Professor and the Scientific Director of the Center for Cellular Therapy, at the Medical Univeristy of South Carolina, USA. Dr. Wang has published more than 50 papers in reputed journals and has been serving as an editorial board member of repute.

His research interest includes Cell Therapy, Stem cell, surgery, Gene therapy

SIMONE PACINI has completed his PhD in 1997. Until 2003 he was active in oncohematology and responsible of flow cytometry and cell sorting facility. Later, his studies focused on clinical use of MSCs and participated actively on isolation of a novel progenitor of MSC in adult human bone marrow. He is currently working in collaboration reputed Universities and Medical Colleges. Actaually, he is lab director of the “Michele Cavaliere Laboratories for Cell Therapy ” at University of Pisa. He has published more than 40 papers in reputed journals and he is editorial board member of the Frontiers in Cell Developmental Biology journal.

His research interests includes cell therapy, cell development, oncohematology, cell sorting.

Farzin Farzaneh holds the Chair of Molecular Medicine at King’s College London. He has published over 250 research articles with an average citation of over 30, and an Impact Factor of 47. He has run a licensed GMP facility at King’s College London, since 2001, for the production of cell and gene therapy based investigational medicinal products. Farzin has extensive industrial and academic collaborations, including research council, charitable and pharmaceutical sponsorships of £25M. He has initiated a number of clinical trials in novel applications of gene therapy and holds MHRA licences (IMPs and “Specials"). He is a Qualified Person (QP) for release of cell and gene therapy products in UK and EU and an Individual Designate under a Human Tissue Authority licence that allows procurement, testing, processing, distribution and/or import/export of tissues and or cells intended for human applications. He is also appointed by the Commission on Human Medicines, as a member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group since 2016.

Farzaneh research interest includes Cell and Gene Therapy, Tissue science, Human Medicines, Clinical Trials, Biologicals & Vaccines

Jehad Zweiri, lecturer in Cancer studies at the University of Liverpool Medical School, born and grew up in Jordan and received his Bachelor’s degree from the University of Jordan in 1990. He obtained his master degree from London School of Hygiene and Tropical Medicine/University of London, and then obtained his PhD degree in 2000 from Kings College Medical School/University of London, in the field of Immune Gene Therapy of Cancer under the supervision of Professor Farzin Farzaneh. He then started his work as Postdoctoral Associate at the department of Immunology and Medicine at the University of Liverpool in 2002. In 2010 he was appointed as a lecturer in the university of Liverpool medical school and he is currently fellow of the British Higher Education Academy since 2012.

His research interests include Gene Therapy, Cancer Studies, Immunology, Medicine

Sergey Suchkov received his MD from Astrakhan State Medical University. In 1985, he received his PhD from the I M Sechenov Moscow Medical Academy and in 2001, his Doctorship Degree at the Nat Institute of Immunology, Russia. From 1987 through 1989, he was a Senior Researcher, Koltzov Institute of Developmental Biology. From 1989 through 1995, he was a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, he was the Chair of the Department of Clinical Immunology, Moscow Clinical Research Institute. He was an Exe Secretary-in-Chief of the Editorial Board of Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, he is a Chair at the Department for Personalized and Translational Medicine, I M Sechenov First Moscow State Medical University. He is a Member of the New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research) and PMC (Personalized Medicine Coalition), Washington, USA.

Translational Medicine

Frank Staal is full professor of Molecular Stem Cell biology at Leiden University School of Medicine (LUMC). He is co-director of the LUMC Flow Cytometry Core Facility (FCF) and holds teaching positions at Delft University of Technology and Erasmus MC, Rotterdam, The Netherlands. He was a postdoctoral Fellow of the Royal Academy of Arts and Sciences, member of the Health Council that advises the Dutch Government (on neonatal screening) and coordinates two large EU H2020 consortia on gene therapy for immune disorders. The research of Frank J.T. Staal focuses on molecular regulation of immature T lymphocyte development and hematopoietic stem cell biology.

Retroviral transduction; Gene therapy; Stem cell assays; FTOC; Reporter gene assays; Immunology assays; T cell clones; Molecular biological techniques; Protein chemistry; Kinase assays

Tengiz Tkebuchava, American, Russian, Swiss Cardiac surgeon. He was the founder of BTT (BostonTransTec) President Pro Georgia, since 1993. Member American Association for the Advancement of Science, New York Academy Science, Association Swiss Physicians. He did Medical diploma, State Medical U., Tbilisi, Georgia, 1982; Doctor of Philosophy, Bakulev Institute, 1990. His career as Researcher, Institute Cardiovascular Surgery, Moscow, 1981-1982; surgeon, Eastern State Hospital, Tbilisi, 1982-1985; cardiac surgeon, Bakulev Institute Cardiovascular Surgery, Moscow, 1985-1989; researcher, Paul Sherer Institute, Brugg, Switzerland, 1990; cardiac surgeon, U. Hospital Zürich, Switzerland, since 1991. Director Project for Development of Cardiovascular Surgery, Georgia.

Cardiac ablation, stem cells, drugs, hydrogels, gene therapy and others

Dr. Dayong Gao is a Professor of Mechanical Engineering and Adjunct Professor of Bioengineering at the University of Washington College of Engineering, Seattle, WA. He is an academician of Washington State Academy of Sciences. Prior to joining the University of Washington, he was a Professor of Mechanical Engineering and Biomedical Engineering at the University of Kentucky, where he was elected and honored as Endowed Alumni Professor and Baxter Healthcare Corp Chair in Engineering. Dr. Gao’s work has been recognized and supported through numerous awards and grants from research funding agencies, including National Institutes of Health (NIH), Department of Defense, National Science Foundation, National Cancer Society, American Heart Association, Bill and Melinda Gates Foundation, Whitaker Foundation, Washington Research Foundation, and many industries. Supported by major grants from the Bill & Melinda Gates Foundation and NIH, he currently serves as the Director and PI of an international consortium to investigate and develop optimal conditions and technology for cryopreservation of human mucosal immune cells and tissues for HIV vaccine and new drug/microbicide development and assessment.

Fundamental and applied cryobiology: revealing the mechanisms of cryoinjury to living biological systems at low temperatures, development of optimal methods, novel technology and instruments for long-term cryopreservation/banking of living cells, tissues and organs for cellular and gene therapy, tissue engineering, regenerative medicine and organ transplantation; Development of a new generation of artificial organs, especially artificial kidney and liver systems for treatment of end-stage kidney and liver failure; Bio-instruments and micro/nano-sensors (BioMEMS) for rapid and cost-effective diagnosis of diseases with high sensitivity and specificity.

James K.Williams have been at Wake Forest University for 30 years. During that time, his research focus has been women’s health. While now a faculty member of Regenerative Medicine, his past research focused on the use of animal models to explore the effects of aging and sex hormones on the cardiovascular and urogenital systems. When moving to the Wake Forest Institute for Regenerative Medicine (WFIRM), his focus remained on women’s health and was funded for 4 years and now funded for an additional 4 years to explore the utility of cell therapy for urinary incontinence – using nonhuman primates as the animal model.

Cell Therapy,Estrogen Replacement Therapy,Ovariectomy

Professor Dr. Luisa Maria Arvide Cambra, Spanish is now Professor with Chair at the University of Almería (Spain). She also taught at the University of Granada, Spain. Thirty four years of teaching and researching experience. She is Director of Research Group HUM113-Estudios Filológicos from Program of Research of Andalusian Government, where she has managed and directed several academic and scientific contracts and research projects.She is author of a many works on several aspects of the Arabic science and literature in the Middle Ages, as well as Arabic language and linguistics. She has also participated in different prestigious international scientific conferences and visited many Universities and academic institutions in Europe, United States and Arab countries to teach and research.

Philological studies,Humanities

Dr. Yang is an Associate Professor in Department of Anatomy & Cell Biology, University of Pennsylvania, School of Dental Medicine. She received her MD (1994) and PhD (2000) in China. She then completed postdoctoral fellowships in bone biology at The Forsyth Institute & Harvard School of Dental Medicine and the University of Michigan School of Dentistry. She was appointed an assistant Professor in Department of Oral Biology, in State University of New York at Buffalo in 2008 and then became a tenured associate professor in 2014, She joined University of Pennsylvania in June 2016. She is an author of over 50 papers published in international journals including Nature Communication, Cell Death & Differentiation, Journal of Bone & Mineral Research, Human Molecular Genetics, a reviewer for numerous journals and editorial board of several journals. She and her lab members are the recipients of numerous research awards including Most outstanding abstract award for top one abstract in American Society of Bone and Mineral Research Annual Meeting, ASBMR-John Haddad Young investigator award, Young Investigator Award. Dr. Yang’s lab has pursued innovative research on the mechanisms of bone formation and resorption, including craniofacial and bone development, metabolism and mechanostransduction, and stem cell-mediated bone regeneration.

Craniofacial and bone development, bone remodeling and mechanotransduction, stem cell and gene therapy mediated bone repair and regeneration.

A Yilmazer is working as an Assistant Professor in the Biomedical Engineering Department of Ankara University. She has been the Vice Director of the Stem Cell Institute of Ankara University since December 2016. She completed her MSc degree in Cancer Immunotherapy from the University of Nottingham (UK) and obtained her PhD in the Nanomedicine Lab based in the School of Pharmacy, University College London. She has published papers on nanomedicine, cancer therapy and cellular reprogramming in various distinguished journals

Cell Therapy, Gene Therapy, Nano Medicine, cancer therapy and cellular reprogramming.

Nayef Jarrous is currently working at The Hebrew University of Jerusalem, Israel. His research interest is based on Human nuclear RNase P ribonucleoprotein in tRNA processing. He has published many articles in reputed journals.

Human nuclear RNase P ribonucleoprotein in tRNA processing and transcription

Dr. Brij. M. Gandhi is the Chief Executive Officer and founder of Neo BioMed Services (www.neobiomed.com), a company which provides services and consultancy in health related areas. The Company with a branch office in Cleveland, UK (www.neobiomed.co.uk) serves as the focal point for providing services and solutions to the healthcare community in Europe. His basic skills and experiences is in areas of Management; Research and Development; Policy and Strategic Planning; Market Strategy; Technology Transfer; Sales; Biodefence Strategies; Institutional Development and Regulatory Issues related to biopharmaceuticals, pharmaceuticals, herbals and food safety, biosafety and biosecurity and healthcare areas including stem cell and regenerative medicine. Dr. Gandhi retired in 2006 as Adviser to the Government of India, Ministry of Science and Technology, Department of Biotechnology, after serving for over 18 years in various capacities managing promotion and policy related issues in biotechnology related to international collaborations, medical biotechnology, infrastructure development, animals and aquaculture biotechnology. Prior to that Dr. Gandhi had been a Research Scientist at the All India Institute of Medical Sciences, New Delhi for about twenty years. Dr. Gandhi continues to serve as Advisor / Director to a number of institutions/pharma and biopharma industries including MNCs and has an experience of over 49 years of active service, as research scientist, science manager, adviser/consultant with over 155 publications. Dr.Gandhi also as Director of a Mumbai based Stem Cell Company has been involved in medical practice for regenerative medicine. Dr. Gandhi had his Masters in Biochemistry from PAU and Ph.D. in Experimental Medicine from the University of Bergan, Norway. He was trained at the Massachusetts Institute of Technology, USA; London School of Hygiene and Tropical Medicine, London; National Institutes of Health, Maryland, USA; and University of Bergan, Norway.

Immunology and diagnostics for parasitic, bacterial and viral infections especially amoebic diseases; viral diseases including hepatitis viruses; liver diseases; stem cells and regenerative medicine; food and nutritional health issues.

Decio Basso has earned his Medical degree in 1982 from the Federal University Santa Catarina (UFSC), at Florianopolis, Brazil. He then attended PUC-Pontifical Catholic University of Rio Grande do Sul, Brazil to pursue a specialization Medical Degree Geriatric and Gerontology in 1990; after graduating, he was for an internship continuing education at Harvard Medical School in Boston, USA. He has been an integral part of medical staff at The Department of Immunology at the University of British Columbia, Canada. He is serving as a Professor at UPE (Universidad Privada Del Este, Paraguay). He is the Founder of the Gerobasso Medical Research Center; a medical research organization.

Stem Cells